The U.S. International Trade Commission and other federal bodies launched investigations into Chinese state support and pricing practices in the biotech sector, examining whether government subsidies and market conduct harmed U.S. firms. BioCentury and other outlets reported the probe could lead to tariffs or trade restrictions depending on findings. The inquiries are part of wider trade and national‑security scrutiny of biotechnology supply chains and foreign investment. The investigations aim to map subsidies, procurement practices, and pricing that could distort global competition. Biotech companies with China exposure and investors should expect added regulatory and political risk; the probe could reshape cross‑border collaborations and sourcing strategies if findings prompt remedies.